The Life Sciences team advised Cerevance on its agreement to form a multi-year research alliance with Takeda Pharmaceutical Company Limited to identify novel target proteins expressed in the central nervous system and to develop new therapies against them for certain GI disorders.
Cerevance is a private pharmaceutical company focused on central nervous system diseases. Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.
Scientists from both companies will select, confirm and validate targets from rich gene expression data sets generated by Cerevance’s NETSseq technology, which sorts and profiles specific neuronal and glial cell types in post-mortem human central nervous system tissue at unparalleled depth. Under the terms of the agreement, which includes an upfront technology access fee and research support to Cerevance, Takeda will pay preclinical and clinical milestone payments and royalties to Cerevance as targets are validated and compounds are advanced through development and onto the market worldwide. Cerevance is eligible to receive development, commercialization and sales-based milestone payments that may exceed $170 million on a per target basis.
The Goodwin team was led by partner Noelle Dubiansky and associate Shannyn Henke.
For more details, read the articles in BioSpace, Fierce Biotech and The Pharma Letter.